Clomid vs Femara for Fertility: What Real-World Evidence Actually Shows

What Is Each Drug and How Does It Work in Your Body?

Both clomiphene citrate (Clomid, Serophene) and letrozole (Femara) trigger ovulation by raising your body's follicle-stimulating hormone (FSH), but they do so through completely different mechanisms. That difference matters for how your uterus and cervical mucus respond, which in turn affects embryo implantation.

Clomiphene: The Older Drug With a Complex Estrogenic Footprint

Clomiphene is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors in the hypothalamus, which tricks your brain into sensing low estrogen and releasing more GnRH, then more FSH. The result is follicle growth. The drawback is that clomiphene also blocks estrogen receptors in the endometrium and cervix, thinning the uterine lining and thickening cervical mucus, two changes that work against the embryo it just helped create.

Clomiphene has a long half-life of roughly two weeks. Its metabolites circulate long after the five-day course ends, sustaining those anti-estrogenic effects throughout your luteal phase.

Letrozole: A Different Mechanism, a Cleaner Hormonal Signal

Letrozole is an aromatase inhibitor. It blocks the enzyme that converts androgens into estrogen, causing a transient estrogen drop that drives FSH release. Because letrozole clears your body quickly (half-life approximately 45 hours), estrogen rebounds after the drug finishes, and your endometrium and cervical mucus are not suppressed. This is why most reproductive endocrinologists now prefer it for PCOS and anovulatory infertility.

Letrozole is FDA-approved for postmenopausal breast cancer, not for ovulation induction. Its fertility use is off-label everywhere except Canada, where it received formal approval for this indication in 2018. ASRM's 2020 committee opinion nonetheless endorses letrozole as a first-line agent for ovulation induction in PCOS.

The Head-to-Head Evidence: What the NEJM 2014 Trial Found

The single most important dataset comes from the Legro et al. NEJM 2014 trial, a multicenter, double-blind, randomized controlled trial of 750 women with PCOS (ages 18 to 40, BMI <40 kg/m²) conducted across 12 U.S. Academic centers. Women received up to five cycles of either letrozole 2.5 mg/day or clomiphene 50 mg/day on cycle days 3 through 7.

Primary Outcome: Live Birth

Live birth rate per woman was 27.5% for letrozole versus 19.1% for clomiphene, a statistically significant difference (relative risk 1.44, 95% CI 1.05 to 1.97). That absolute gap of 8.4 percentage points means roughly one additional live birth for every 12 women who switch from clomiphene to letrozole in this population.

Ovulation and Conception Rates

Ovulation per cycle was 61.7% on letrozole versus 48.3% on clomiphene. Cumulative ovulation across five cycles was substantially higher on letrozole. Conception rates followed the same pattern: 31.8% letrozole versus 22.5% clomiphene.

Multiple Pregnancy Risk

This finding surprised many clinicians at the time. The twin rate was 3.4% for letrozole versus 7.4% for clomiphene. Because letrozole tends to produce mono-follicular development while clomiphene more often stimulates two or more follicles, letrozole carries a lower multiples risk. For women with PCOS who already face elevated obstetric risks, that distinction is clinically meaningful.

Miscarriage Rate

Miscarriage rates did not differ significantly between groups (31.4% letrozole versus 28.6% clomiphene). Women with PCOS have elevated baseline miscarriage rates regardless of which ovulation agent is used, likely driven by underlying metabolic and hormonal factors rather than the drug itself.

PCOS Specifically: Why Letrozole Now Leads

PCOS affects roughly 8 to 13% of women of reproductive age, making it the most common cause of anovulatory infertility. In this population, the case for letrozole is the strongest in the literature.

The WomanRx clinical team uses a three-factor framework to assess first-line agent choice in PCOS:

1. Endometrial thickness at baseline. If your lining is already thin (under 7 mm at the start of a monitored cycle), clomiphene's anti-estrogenic effects make it a worse choice before the first egg is ever retrieved.
2. Androgen levels. Women with PCOS who have elevated free testosterone or DHEAS often convert those androgens to estrogen via aromatase. Blocking that conversion with letrozole reduces the androgen excess while stimulating the ovary, a dual benefit clomiphene cannot offer.
3. Body weight and insulin resistance. The Legro trial enrolled women with a mean BMI near 35. Letrozole's advantage over clomiphene was consistent across BMI subgroups, but the absolute benefit was largest in women with obesity, likely because higher adipose aromatase activity gives letrozole more substrate to work with.

ACOG Practice Bulletin 194 states that letrozole is preferred over clomiphene for ovulation induction in women with PCOS when live birth rate is the primary outcome. The Endocrine Society's 2023 PCOS guidelines echo this recommendation.

Unexplained Infertility: A More Even Playing Field

For women with regular ovulatory cycles and a diagnosis of unexplained infertility, the evidence is less one-sided. In this population, ovulation induction is used to superovulate (stimulate one or two extra follicles), not to trigger ovulation from scratch.

The AMIGOS trial (NEJM 2015) compared letrozole, clomiphene, and gonadotropins in 900 couples with unexplained infertility. Live birth rates per couple were 8.9% letrozole, 10.3% clomiphene, and 17.3% gonadotropins per cycle. Neither oral agent significantly outperformed the other in this population, though gonadotropins achieved meaningfully higher rates at the cost of higher multiple pregnancy risk.

What this means for you: if you ovulate on your own and carry an unexplained infertility diagnosis, the choice between letrozole and clomiphene matters less. Your reproductive endocrinologist may reasonably try either, or move directly to intrauterine insemination (IUI) combined with whichever agent you tolerate better.

Switching from Clomid to Femara: When and Why

Switching is appropriate in several clear clinical situations.

Clomiphene Resistance

Approximately 15 to 40% of women with PCOS do not ovulate on clomiphene even at the maximum dose of 150 mg/day. This is called clomiphene resistance. Because letrozole works through a different pathway, ovarian response to letrozole does not depend on the same estrogen receptor sensitivity that clomiphene requires. Published case series suggest up to 50% of clomiphene-resistant women ovulate on letrozole, though live birth data in this specific subgroup are thinner.

Poor Endometrial Response

If your monitoring ultrasound shows a thin endometrium (under 7 mm) on clomiphene despite ovulation, switching to letrozole is reasonable. The restored estrogen environment during the follicular phase on letrozole allows the lining to thicken normally. Several small prospective studies confirm endometrial thickness is greater on letrozole cycles than on clomiphene cycles in anovulatory women.

Recurrent Clomiphene Failures With Confirmed Ovulation

If you are ovulating on clomiphene but not conceiving over three to four cycles, the anti-estrogenic effect on cervical mucus and the endometrium is the most likely culprit. Letrozole removes that problem.

How to Switch

Most protocols move directly from clomiphene to letrozole with no washout required. Because clomiphene has a long half-life, your clinician may recommend one natural cycle before starting letrozole if you experienced any persistent side effects, but this is not universally required.

Side Effects: How Each Drug Feels Day to Day

Both drugs are taken for five days early in your cycle, and most side effects resolve quickly. The side-effect profiles differ in ways that matter practically.

Clomiphene Side Effects in Women

• Hot flashes: Occur in roughly 10% of women and can be severe enough to disrupt sleep.
• Mood changes: Irritability and low mood are reported more often with clomiphene than letrozole, likely because of its prolonged anti-estrogenic central nervous system effects.
• Visual disturbances: Blurring or seeing spots occurs in approximately 1.5% of users. If this happens, stop the drug and contact your provider. Clomiphene should not be restarted if visual symptoms appear.
• Cervical mucus changes: Thicker mucus reduces sperm penetration and may partly explain why ovulation on clomiphene does not always translate to conception.
• Multiple follicle stimulation: Higher twin and triplet rates compared to letrozole.

Letrozole Side Effects in Women

• Hot flashes: Present but generally milder and shorter-lasting than with clomiphene given letrozole's shorter half-life.
• Fatigue and dizziness: More commonly reported with letrozole than clomiphene in the NEJM 2014 trial, though these symptoms are transient.
• Bone pain: Relevant in the oncology context but not clinically significant over a five-day fertility course.
• Headache: Similar frequency to clomiphene.

Neither drug causes a clinically significant increase in congenital anomalies at doses used for ovulation induction, a point addressed in detail below.

Dosing Across Reproductive Life Stage

Both drugs are prescribed during the reproductive years, specifically for women who are not yet pregnant and wish to conceive. Neither is used in perimenopause or postmenopause for fertility purposes.

Standard Dosing Protocols

Clomiphene: Start at 50 mg/day for five days (cycle days 3 to 7 or 5 to 9). If no ovulation, increase by 50 mg increments each cycle to a maximum of 150 mg/day. ACOG recommends limiting clomiphene use to six ovulatory cycles given concerns about ovarian cancer risk with prolonged use (though evidence remains inconclusive) and diminishing returns beyond that point.

Letrozole: Start at 2.5 mg/day for five days (cycle days 3 to 7). Increase to 5 mg/day if no ovulation, and up to 7.5 mg/day if needed. The ASRM 2020 committee opinion supports this dose escalation approach.

Age Considerations

In women over 37, ovarian reserve testing (AMH, antral follicle count) should be completed before starting either oral agent. Both drugs depend on a functioning ovarian reserve, and women with diminished reserve may not respond adequately. In that group, referral directly to injectable gonadotropins or IVF is often more appropriate than spending three months on oral agents.

Pregnancy, Lactation, and Contraception: What You Must Know

This section applies to both clomiphene and letrozole. Both drugs carry serious pregnancy warnings and should be stopped immediately if you conceive.

Clomiphene and Pregnancy

Clomiphene is FDA Pregnancy Category X in established pregnancy. Category X means animal and human data show fetal abnormalities, and the risk outweighs any possible benefit. Clomiphene is taken precisely to achieve pregnancy, but if you inadvertently take it after conception (for example, because you did not know you were pregnant), contact your provider immediately. Clomiphene should not be used in women who are already pregnant.

Letrozole and Pregnancy

Letrozole carries FDA Pregnancy Category D based on animal teratogenicity data. Animal studies at doses higher than those used for ovulation induction show skeletal malformations. Human observational data are reassuring: a large Canadian registry study found no increase in major congenital anomalies in infants born after letrozole-induced cycles compared to natural conception, and the NEJM 2014 trial found no significant difference in congenital anomaly rates between letrozole and clomiphene groups. Still, letrozole must be stopped as soon as pregnancy is confirmed. It is not taken during pregnancy under any circumstances.

Lactation

Neither clomiphene nor letrozole is indicated during lactation. Both are used to achieve pregnancy, not after. If a postpartum woman with PCOS or anovulation wishes to conceive a second pregnancy while still breastfeeding, she should discuss with her provider whether to wean first, as ovulation induction agents have not been adequately studied in the context of active lactation and the hormonal milieu of breastfeeding suppresses ovulation regardless.

Contraception Note

Because both drugs are taken to induce ovulation and conception, contraception is not a goal during treatment. The relevant point is the reverse: women who are already pregnant and unaware of it should not take either drug, and a urine pregnancy test before each cycle of treatment is standard practice in most protocols.

Who Is Each Drug Right For?

Letrozole Is the Better Choice If:

• You have PCOS (anovulatory) and want to maximize live birth rates per the NEJM 2014 data
• You had a thin endometrium (<7 mm) on clomiphene
• You have elevated androgens (common in PCOS), since aromatase inhibition addresses both
• You have had three or more clomiphene cycles without conception despite confirmed ovulation
• You want lower multiple pregnancy risk
• You have insulin resistance or obesity, where the Legro trial showed the strongest letrozole benefit

Clomiphene May Still Be Appropriate If:

• You have unexplained infertility (the AMIGOS trial shows comparable performance)
• Your clinic or country has specific protocol or cost constraints (clomiphene is cheaper and available generically worldwide)
• You have already ovulated and conceived on clomiphene without endometrial problems
• Letrozole is not accessible (limited formulary coverage in some markets)

Neither Drug Is Right If:

• You have diminished ovarian reserve (low AMH, fewer than 5 to 7 antral follicles)
• You have tubal factor infertility (ovulation induction does not address a blocked tube)
• Your male partner has severe oligospermia or azoospermia
• You have already failed six cycles of oral agents, where escalation to injectable gonadotropins or IVF is the evidence-based next step

What Women Are Under-Represented in the Trials?

The evidence base here is larger than for many women's-health topics, which is worth acknowledging. The NEJM 2014 Legro trial is one of the better-powered fertility RCTs in existence, and it enrolled only women. However, specific subgroups remain understudied.

Women over 40 with PCOS were largely excluded from major trials; the Legro trial capped age at 40. Women with PCOS and co-existing endometriosis have not been studied in dedicated letrozole-versus-clomiphene trials. Black and Hispanic women were enrolled in the Legro trial (approximately 22% and 13% of the sample, respectively), but subgroup analyses by race were not powered to detect differences. Given that PCOS presentation and metabolic risk differ by ethnicity, this is a real evidence gap. ASRM has acknowledged this gap in its 2020 statement and calls for more diverse recruitment in future ovulation induction trials.

Real-World Practice: What Reproductive Endocrinologists Are Doing Now

In U.S. Academic reproductive medicine centers, letrozole has effectively displaced clomiphene as the first-line oral ovulation induction agent for PCOS over the past decade. A 2022 survey of ASRM members found letrozole is now the initial choice for PCOS in over 80% of responding reproductive endocrinologists. Clomiphene remains more common in general OB-GYN practices, largely because of familiarity, lower cost, and the fact that many generalists started prescribing it before the 2014 NEJM data were available.

"The 2014 Legro data were practice-changing for those of us in subspecialty care," says Dr. Elena Vasquez, MD, reproductive endocrinologist and WomanRx medical reviewer. "But I still see women referred to me after four or five cycles of clomiphene who were never told letrozole existed. The information gap between subspecialty and primary care is the biggest barrier to women getting the right drug first."

If you are seeing a general gynecologist for ovulation induction, asking specifically about letrozole is reasonable. The ASRM endorsement and the NEJM 2014 data are sufficient clinical justification for any licensed prescriber to offer it.

Monitoring Your Cycle on Either Drug

Both drugs should ideally be used with at least some monitoring, particularly if this is your first cycle on a new agent.

• Transvaginal ultrasound on approximately cycle day 10 to 12 checks follicle size (a mature follicle is roughly 18 to 22 mm) and endometrial thickness.
• LH urine testing (OPKs) or a trigger shot (hCG 5,000 to 10,000 IU or recombinant hCG 250 mcg) times intercourse or IUI.
• Serum progesterone at 7 days post-ovulation confirms the luteal phase response. A value above 3 ng/mL confirms ovulation; above 10 ng/mL suggests adequate luteal function.

Unmonitored cycles are practiced in some settings due to cost but miss the endometrial thickness data that can inform a switch between agents.